Stockscreener 앱 받기
9.89
4.21%
0.40
시장 영업 전:
9.85
-0.04
-0.40%
전일 마감가:
$9.49
열려 있는:
$9.68
하루 거래량:
5.06M
Relative Volume:
1.08
시가총액:
$1.61B
수익:
$1.08B
순이익/손실:
$422.82M
주가수익비율:
4.3377
EPS:
2.28
순현금흐름:
$-637.33M
1주 성능:
+3.78%
1개월 성능:
+19.59%
6개월 성능:
+26.96%
1년 성능:
+28.78%
1일 변동 폭
$9.1394
$10.11
1주일 범위
$9.1394
$11.97
52주 변동 폭
$5.01
$11.97
노바백스 Stock (NVAX) Company Profile
명칭
Novavax Inc
전화
240-268-2000
주소
21 FIRSTFIELD RD, GAITHERSBURG, MD
Compare NVAX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NVAX
Novavax Inc
|
9.89 | 1.54B | 1.08B | 422.82M | -637.33M | 2.28 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
노바백스 Stock (NVAX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-08-28 | 재개 | H.C. Wainwright | Buy |
| 2025-08-20 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2025-06-17 | 개시 | Citigroup | Sell |
| 2025-02-28 | 개시 | BTIG Research | Buy |
| 2024-07-30 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2024-05-10 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2024-05-10 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2023-08-09 | 업그레이드 | B. Riley Securities | Neutral → Buy |
| 2023-04-20 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-03-01 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2023-01-09 | 재확인 | B. Riley Securities | Buy |
| 2022-12-30 | 재확인 | H.C. Wainwright | Buy |
| 2022-12-02 | 개시 | Jefferies | Hold |
| 2022-09-22 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-05-20 | 개시 | BofA Securities | Underperform |
| 2022-02-23 | 재확인 | B. Riley Securities | Buy |
| 2022-02-22 | 재개 | Jefferies | Buy |
| 2022-01-21 | 개시 | Cowen | Outperform |
| 2021-05-12 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-12-14 | 개시 | Jefferies | Buy |
| 2020-08-06 | 재확인 | H.C. Wainwright | Buy |
| 2020-08-05 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-08-05 | 다운그레이드 | Ladenburg Thalmann | Neutral → Sell |
| 2020-07-16 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-08 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2020-06-29 | 재확인 | B. Riley FBR | Buy |
| 2020-06-29 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-05 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2020-05-28 | 재확인 | B. Riley FBR | Buy |
| 2020-05-12 | 재확인 | H.C. Wainwright | Buy |
| 2020-04-30 | 재확인 | H.C. Wainwright | Buy |
| 2019-11-27 | 재개 | B. Riley FBR | Buy |
| 2019-08-14 | 재확인 | H.C. Wainwright | Buy |
| 2019-02-28 | 다운그레이드 | Piper Jaffray | Overweight → Underweight |
| 2018-12-18 | 개시 | Ladenburg Thalmann | Buy |
| 2018-12-11 | 개시 | Oppenheimer | Outperform |
| 2018-11-26 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2018-09-21 | 업그레이드 | JP Morgan | Underweight → Overweight |
| 2018-03-29 | 업그레이드 | Seaport Global Securities | Neutral → Buy |
모두보기
노바백스 주식(NVAX)의 최신 뉴스
Novavax, Inc. $NVAX Stock Position Lowered by Vanguard Group Inc. - MarketBeat
Novavax (NVAX) EVP Elaine O'Hara receives major RSU and option grants - Stock Titan
[Form 4] NOVAVAX INC Insider Trading Activity - Stock Titan
Novavax Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
NVAX: Pivoting to a partnership-driven model, the company targets profitability by 2028 with robust pipeline and deals - TradingView
Is Novavax, Inc. (NVAX) a Good Buy at the Moment? - Bitget
Is Trending Stock Novavax, Inc. (NVAX) a Buy Now? - Yahoo Finance
NVAX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
NVAX Stock Rises Overnight Ahead Of Q4 Print With Pfizer Tailwinds — Analyst Warns Of 20% Crash - Stocktwits
Trading Systems Reacting to (NVAX) Volatility - Stock Traders Daily
Sanofi Takes Charge of Novavax COVID Vaccine, Mixed Financial Projections Ahead - StocksToTrade
Novavax Swings To Profit In Q4 Fueled By Nuvaxovid-Linked Revenue - Stocktwits
Novavax, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:NVAX) 2026-02-28 - Seeking Alpha
Novavax Stock Faces Uncertain Future Amid Low Revenue Guidance - StocksToTrade
Assessing Novavax (NVAX) Valuation After Surprise Q4 Profitability And New Pfizer Licensing Deal - Yahoo Finance
How The Novavax (NVAX) Story Is Shifting Toward Licensing Income And COVID Recalibration - Yahoo Finance
Novavax Inc. stock underperforms Friday when compared to competitors - MarketWatch
Novavax (NASDAQ:NVAX) Trading Down 9.8%Here's What Happened - MarketBeat
Why Novavax (NVAX) Shares Are Falling Today - Finviz
Novavax: The Bear Case Is Broken, But The Bull Case Needs More Proof (NASDAQ:NVAX) - Seeking Alpha
Novavax (NASDAQ:NVAX) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
Novavax, Inc. (NASDAQ:NVAX) Q4 2025 Earnings Call Transcript - Insider Monkey
H.C. Wainwright raises Novavax stock price target on guidance beat - Investing.com
NVAX: HC Wainwright & Co. Raises Price Target Amidst Buy Rating - GuruFocus
Novavax Stock Gains as Q4 Earnings & Sales Beat Estimates - Zacks Investment Research
NVAX Q4 Deep Dive: Partnership-Led Strategy and Pipeline Transition Shape Outlook - Finviz
Why Novavax (NVAX) Is Up 10.2% After Partnership-Fueled Return To Full-Year Profitability – And What's Next - Sahm
Novavax Stock Hits Over 1-Year High: Is Sanofi’s Flu-COVID Shot The Post-Pandemic Growth Driver? - Stocktwits
Decoding Novavax Inc (NVAX): A Strategic SWOT Insight - GuruFocus
Novavax Q4 Earnings Call Highlights - MarketBeat
Novavax (NASDAQ:NVAX) Posts Quarterly Earnings Results, Beats Expectations By $0.77 EPS - MarketBeat
What's Going On With Novavax Stock On Friday? - Bitget
NVV1.F Novavax, Inc. (XETRA) up 15.65% pre-market 27 Feb 2026: earnings catalyst - Meyka
Novavax Inc (NVAX) Q4 2025 Earnings Call Highlights: Revenue Surge and Strategic Partnerships ... By GuruFocus - Investing.com Canada
Novavax (NVAX) Turns Profitable With US$440 Million TTM Net Income Challenging Bearish Views - simplywall.st
Novavax to Participate in Upcoming Investor Conferences - GuruFocus
Novavax raises revenue forecast on boost from vaccine deals, shares soar - marketscreener.com
Novavax faces investor questions at three March healthcare events - Stock Titan
Novavax jumps as Q4 profit, higher revenue, and partnership milestones highlight a pivot to licensing - Quiver Quantitative
Novavax (NVAX) Reports Strong Q4 2025 Revenue Growth and Strategic Partnerships - GuruFocus
Novavax outlook 2026 adjusted total revenue $230 mln$270 mln - marketscreener.com
Novavax raises 2026 adjusted revenue outlook on strength in vaccine deals - marketscreener.com
COVID-19 Vaccine Maker Novavax Swings To Profit As Sales Climb - Benzinga
Why Is Novavax (NVAX) Stock Soaring Today - Yahoo Finance
Novavax’s stock soars on expected revenue jump from big pharma deals - The Business Journals
Novavax Q4 2025 slides: earnings beat fuels partnership transformation - Investing.com
Novavax Q4 2025 slides: earnings beat fuels partnership transformation By Investing.com - Investing.com South Africa
Novavax (NVAX) Beats Q4 Earnings and Revenue Estimates - Yahoo Finance
Novavax Q4 Earnings Preview: Wall Street Expects Wider Losses Amid Diversification Efforts - Stocktwits
Novavax Sees Unusually High Options Volume (NASDAQ:NVAX) - MarketBeat
Earnings call transcript: Novavax Q4 2025 earnings beat expectations, stock rises - Investing.com India
노바백스 (NVAX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.11%
6.00%
자본화:
|
볼륨(24시간):